C4 Therapeutics, Inc. - Common Stock (NQ: CCCC )
3.100 -0.300 (-8.82%) Streaming Delayed Price Updated: 4:00 PM EDT, Mar 30, 2023 Add to My Watchlist
Headline News about C4 Therapeutics, Inc. - Common Stock
Where C4 Therapeutics Stands With Analysts
March 28, 2023
Looking Into C4 Therapeutics's Return On Capital Employed
February 28, 2023
Why Fulcrum Therapeutics Shares Are Trading Lower By Over 55%? Here Are Other Stocks Moving In Friday's Mid-Day Session
February 24, 2023
Gainers Bridger Aerospace Group Holdings, Inc. (NASDAQ: BAER) shares jumped 129.6% to $10.15. Jeffrey E. Kelter reported a 22.4% stake in a 13D filing on Thursday.
Benzinga's Top Ratings Upgrades, Downgrades For February 24, 2023
February 24, 2023
C4 Therapeutics's Return On Capital Employed Overview
November 23, 2022
12 Health Care Stocks Moving In Wednesday's Intraday Session
January 25, 2023
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
December 19, 2022
Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.
12 Health Care Stocks Moving In Thursday's Intraday Session
November 24, 2022
Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2022
November 04, 2022
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022
October 11, 2022
C4 Therapeutics Doses First Patient in Phase 1/2 Trial of CFT8634 For SMARCB1-perturbed cancers
May 16, 2022
C4 Therapeutics, Inc. (C4T) (NASDAQ: CCCC) has dosed the first patient in the Phase 1/2 clinical trial of its drug candidate CFT8634, for the treatment of SMARCB1-perturbed cancers, including synovial...
BMO Capital Maintains Outperform Rating for C4 Therapeutics, Lowers Price Target To $20
April 11, 2022
BMO Capital has decided to maintain its Outperform rating of C4 Therapeutics (NASDAQ:CCCC) and lower its price target from $57.00 to $20.00. Shares of C4 Therapeutics are trading down 20.49% over the...
The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More
April 10, 2022
Biotech stocks managed to carve out modest gains for the week ending April 8, defying the broader market weakness. The defensive nature of the stocks make them appealing in times of risk aversion.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following